Y Intercept Hong Kong Ltd Acquires 291,696 Shares of Xeris Biopharma Holdings, Inc. $XERS

Y Intercept Hong Kong Ltd grew its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 655.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 336,214 shares of the company’s stock after acquiring an additional 291,696 shares during the quarter. Y Intercept Hong Kong Ltd owned 0.21% of Xeris Biopharma worth $1,570,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Nuveen LLC purchased a new position in Xeris Biopharma in the 1st quarter worth $12,240,000. Parkman Healthcare Partners LLC grew its stake in shares of Xeris Biopharma by 207.8% during the first quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company’s stock valued at $9,775,000 after buying an additional 1,201,943 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares during the period. Invesco Ltd. lifted its stake in shares of Xeris Biopharma by 1,387.8% in the 1st quarter. Invesco Ltd. now owns 1,026,838 shares of the company’s stock valued at $5,637,000 after acquiring an additional 957,822 shares during the last quarter. Finally, Driehaus Capital Management LLC boosted its holdings in Xeris Biopharma by 137.6% during the 1st quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company’s stock valued at $7,749,000 after acquiring an additional 817,525 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. HC Wainwright initiated coverage on Xeris Biopharma in a research note on Tuesday, August 12th. They issued a “buy” rating and a $10.00 price target on the stock. Zacks Research downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Leerink Partners upped their price target on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a report on Tuesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, October 8th. Finally, Oppenheimer upped their price objective on shares of Xeris Biopharma from $8.00 to $18.00 and gave the company an “outperform” rating in a research note on Wednesday. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $8.92.

Xeris Biopharma Stock Down 0.1%

NASDAQ:XERS opened at $9.70 on Friday. The firm’s fifty day simple moving average is $8.28 and its 200 day simple moving average is $6.21. The stock has a market cap of $1.57 billion, a P/E ratio of -46.19 and a beta of 0.39. Xeris Biopharma Holdings, Inc. has a twelve month low of $2.82 and a twelve month high of $10.02.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million during the quarter, compared to analysts’ expectations of $64.58 million. On average, analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Insider Activity at Xeris Biopharma

In related news, Director Jeffrey W. Sherman sold 42,232 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $7.92, for a total transaction of $334,477.44. Following the sale, the director directly owned 219,188 shares in the company, valued at $1,735,968.96. The trade was a 16.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Dawn Halkuff sold 42,500 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total value of $309,400.00. Following the completion of the transaction, the director owned 115,000 shares of the company’s stock, valued at approximately $837,200. This trade represents a 26.98% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 207,732 shares of company stock valued at $1,550,437. 6.47% of the stock is currently owned by corporate insiders.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.